Navigation Links
Novel Hepatitis C Drug Holds Promise: FDA
Date:4/27/2011

WEDNESDAY, April 27 (HealthDay News) -- An experimental new drug that may treat hepatitis C more effectively than earlier medications will be reviewed Thursday by a panel of experts for the U.S. Food and Drug Administration.

Telaprevir, made by Vertex Pharmaceuticals of Cambridge, Mass., would be prescribed in combination with two existing drugs to help reduce levels of the virus, which can cause severe liver damage, according to documents posted by the FDA on its website in advance of the meeting.

While the older drugs -- pegylated interferon-alfa and ribavirin -- are intended to bolster the immune system's response to hepatitis, the new drug works differently, blocking protease, an enzyme that enables the hepatitis C virus to reproduce. Together, the combined medications may offer new hope for the thousands of Americans with the contagious liver disease.

"A drug like telaprevir does an amazing job clearing the virus, but there's a small portion that is just intrinsically less responsive and it's the job of the older drugs to clear up that mess that's left behind," Dr. Camilla Graham, Vertex's vice president for global medical affairs, told the Associated Press.

According to one of the Vertex studies reviewed by the FDA, 79 percent of hepatitis C patients treated for the first time with the three-drug cocktail -- telaprevir and the two older drugs -- were cured, compared to 46 percent of patients given the earlier drugs alone, the AP reported.

The three-drug combo also worked better than the earlier drugs for patients previously treated for hepatitis C. Sixty-five percent of the telaprevir patients were cured, compared with 17 percent of those taking the older medications, the news service said.

By adding telaprevir to the medication regimen, most patients are cured in six months, instead of 12 months, which reduces their exposure to uncomfortable side effects, the AP reported.

The new drug was less effective for blacks than whites, the FDA said.

On Wednesday FDA reviewers were expected to study a similar drug, boceprevir, made by Merck & Co.

Telaprevir's cure rates appear to be better than boceprevir's, the AP reported.

On Thursday, the committee of outside experts will be asked for its comments and recommendations on telaprevir. The FDA is not required to follow the advice of its advisory panels, but it usually does so.

The U.S. Centers for Disease Control and Prevention estimated 17,000 new hepatitis C virus infections in the United States in 2007. Many people with the disease have no symptoms until it has caused liver damage, sometimes so severe that a liver transplant is needed.

Until the early 1990s, when testing of the nation's blood supply became routine, hepatitis C was often contracted from blood transfusions. Today it is most commonly associated with injection drug use. It is also transmitted through sexual contact with an infected person, the CDC said.

Earlier this year, a study from the Johns Hopkins School of Public Health called for greater efforts to reduce the population of hepatitis C-infected injection drug users. That study found that new cases of hepatitis C were decreasing only among younger injection drug users who had recently starting using the drugs.

More information

To learn more about hepatitis C, visit the U.S. National Library of Medicine.

-- HealthDay staff

SOURCES: U.S. Centers for Disease Control and Prevention; Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. A potential novel drug-target for colorectal cancer treatment comes from the brain
2. Researchers identify novel pathophysiologic mechanism responsible for autoimmunity
3. Novel association between Parkinsons disease and prostate cancer
4. Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma
5. Penn researchers uncover novel immune therapy for pancreatic cancer
6. Novel Treatment for Pancreatic Cancer Under Study
7. Novel approaches to bacterial caries management: An efficacious solution in view?
8. Novel strategies target health care-associated infections
9. Novel clinical trial aims to reduce recurrence of aggressive breast cancer
10. A novel prognostic marker for biliary atresia
11. Genome sequencing used to assess a novel form of Clostridium botulinum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... August 18, 2017 — ... advocating for active, healthy lifestyles and highlighting the importance of proactive eye and ... impairments and shares the latest innovations in hearing aid technology. , According ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... protection services and financial consultations to communities throughout the greater DC region, is ... with the goal of rescuing local animals and training them to be companions ...
(Date:8/18/2017)... John, IN (PRWEB) , ... August 18, 2017 , ... ... to communities in northwest Indiana, is campaigning in support of Campagna Academy in a ... referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a nonprofit ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 active patients, ... replacement therapy and integrative medicine, has become a frontrunner for people seeking help ... menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 by ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... tracking and monitoring solutions, announced today the launch of a redesigned corporate website, ... navigation and aesthetic, fully responsive design, and an enhanced search directory for businesses ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Aug. 2, 2017 Fenita J. ... as a Pinnacle Lifetime Professional in the Field ... Manager at Turing Pharmaceuticals, AG. Her skills and ... relationship building.                ... 25 years of experience as a highly successful ...
(Date:8/2/2017)... 2017 CaryRx, a next-generation full-service pharmacy, has announced ... patients in the Washington D.C. metropolitan ... providing delivery of medications through the convenience of its patient-friendly ... delivered within one hour to any location in D.C. ... this invaluable service to Washington D.C. ," says ...
(Date:7/31/2017)... MEMPHIS, Tenn. , July 31, 2017 Three Tru-D ... in Yongsan, South Korea . Tru-D, short for "Total ... patient and operating rooms after an environmental services (ES) professional cleans the ... ... "Although ...
Breaking Medicine Technology: